This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up
by Zacks Equity Research
Alnylam stock jumps 15% after a surprise Q2 profit, driven by soaring Amvuttra sales and raised 2025 revenue guidance.
Nonfarm Payrolls Come in SIgnificantly Below Expectations
by Zacks Equity Research
Nonfarm Payrolls Come in SIgnificantly Below Expectations.
Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
by Zacks Equity Research
REGN stock up as Q2 EPS jumps 12% on strong Eylea HD and Dupixent profits, beating revenue and earnings estimates.
Jobs Shrink in the Summer of '25, Pre-Markets Lower
by Mark Vickery
+73K new jobs were filled last month, lower than the +100K expected. The Unemployment Rate ticked up 10 bps.
Regeneron (REGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of +60.52% and +9.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Sanofi Q2 Earnings & Sales Miss, 2025 Top-Line View Raised, Stock Down
by Zacks Equity Research
SNY misses Q2 earnings and sales estimates but lifts 2025 sales outlook on strong Dupixent and vaccine momentum.
Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -10.53% and -19.33%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Unlocking Q2 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top-and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?
by Zacks Equity Research
Strong Dupixent profits and rising Eylea HD demand may help Regeneron offset pressure in its Q2 earnings report.
Roche Reports 7% 1H25 Sales Growth, Key Drugs Perform Well
by Zacks Equity Research
RHHBY posts solid first-half 2025 growth on strong drug demand, but pipeline setbacks and biosimilar hits remain headwinds.
Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?
by Zacks Equity Research
Eylea's sales slump and pipeline setbacks have dragged REGN down 22.8% YTD, underperforming its peers and the S&P 500.
BAYRY Skyrockets 62.9% YTD: Should You Buy or Sell the Stock?
by Zacks Equity Research
Bayer's shares are up 62.9% YTD as new drug approvals and a streamlined model fuel a sharp pharma turnaround.
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
by Zacks Equity Research
NTLA stock surges 29.8% in a month, driven by gene therapy pipeline progress and growing investor attention.
FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug
by Zacks Equity Research
REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?
by Sundeep Ganoria
CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.
Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?
by Kinjel Shah
SNY trades below key moving averages but strong Dupixent growth, pipeline wins and rising estimates may keep bulls invested.
Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid
by Zacks Equity Research
SNY and REGN's Dupixent gets FDA approval for a rare and chronic skin disease, marking its eighth approved indication for the drug.
Stock Market News for Jun 10, 2025
by Zacks Equity Research
U.S. stock markets were muted and closed mixed on Monday.
Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space
by Ekta Bagri
SNY, BMY, REGN and others ramp up 2025 dealmaking as pharma/biotech giants chase innovation across key growth areas.
Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise?
by Sundeep Ganoria
Emrelis wins FDA approval, marking ABBV's first lung cancer drug and strengthening its oncology reach into solid tumors.
REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?
by Zacks Equity Research
REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline setbacks.